Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: Updated results from PROFILE 1014

Overview

cited authors

Mok, T. S. K., Kim, D-W., Wu, Y-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Wilner, K., Blackhall, F., Solomon, B. J.

funding text

Pfizer.

authors

Mekhail, Tarek M., MD

Publication Date

September 1, 2017

webpage

Web of Science

published in

ANNALS OF ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.